IDXX vs RNAC · P/E 40, rev $2.36B vs P/E 2.1, rev $78.0K
IDEXX Laboratories Inc (IDXX) versus Cartesian Therapeutics Inc. (RNAC) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Latest reported RNAC revenue for 2026-06-30 was $78.0K. Net income was -$23.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Not investment advice. Open the IDXX and RNAC stock pages for the full models.
Not investment advice.